Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E0771 cultured mouse mammary tumor cell RNA-seq gene expression profiling: impact of activated cyclophosphamide versus interferon-beta, and the role of interferon signaling in cyclophosphamide responses

ABSTRACT: E0771 cultured mouse mammary tumor cell RNA-seq gene expression profiling: impact of activated cyclophosphamide versus interferon-beta, and the role of interferon signaling in cyclophosphamide responses

PROVIDER: PRJNA787495 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17179957_1.fastq.gz	Fastqsanger.gz
	SRR17179957_2.fastq.gz	Fastqsanger.gz
	SRR17179958_1.fastq.gz	Fastqsanger.gz
	SRR17179958_2.fastq.gz	Fastqsanger.gz
	SRR17179959_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

E0771 cultured mouse mammary tumor cell RNA-seq gene expression profiling: impact of activated cyclophosphamide versus interferon-beta, and the role of interferon signaling in cyclophosphamide responses

Project description:RNA-seq analysis of polyA-selected RNA isolated from cultured E0771 mouse breast cancer cells, with or without treatment with activated cyclophosphamide (4HC, 4-hydroperoxy-cyclophosphamide), interferon-beta, and antibody to the type-I interferon receptor IFNAR1. These RNA samples were part of a study where we investigated the role of type-I interferon signaling in therapeutic responses to cyclophosphamide in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190534 | GEO

4T1 cultured mouse mammary tumor cell RNA-seq gene expression profiling: impact of activated cyclophosphamide versus interferon-beta treatment, and the role of interferon signaling in cyclophosphamide responses

Project description:RNA-seq analysis of polyA-selected RNA isolated from cultured 4T1 mouse breast cancer cells, with or without treatment with activated cyclophosphamide (4HC, 4-hydroperoxy-cyclophosphamide), interferon-beta, and antibody to the type-I interferon receptor IFNAR1. These RNA samples were part of a study where we investigated the role of type-I interferon signaling in therapeutic responses to cyclophosphamide in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190533 | GEO

E0771 mouse mammary tumor RNA-seq gene expression profiling: impact of time course of metronomic cyclophosphamide treatment of triple negative breast cancer tumors implanted in female C57/BL6N mice

Project description:RNA-seq analysis of polyA-selected RNA isolated from frozen tumor tissue excised from adult female C57/BL6N mice implanted with E0771 tumors in the mammary fat pad. Mice were treated with cyclophosphamide given on a metronomic schedule (treatment at 130 mg/kg per injection, or PBS (vehicle control)) (lab experiment # TD229). Tumor tissue was collected and used for RNAseq analysis at the following time points: day 1, day 2, day 3, day 6, and day 12, with cyclophosphamide treatments given on day 0, and then again on day 6 in the case of the day 12 time point. These tumor RNA samples were part of a study where we investigated the role of type-I interferon signaling in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190532 | GEO

Project description:4T1 cultured mouse mammary tumor cell RNA-seq gene expression profiling: impact of activated cyclophosphamide versus interferon-beta treatment, and the role of interferon signaling in cyclophosphamide responses

| PRJNA787496 | ENA

Cyclophosphamide treatment experiments in mouse models of breast cancer: 4T1 and E0771

Project description:Cyclophosphamide treatment experiments in mouse models of breast cancer: 4T1 and E0771

| PRJNA787482 | ENA

E0771 WXS

Project description:E0771 whole exom sequencing

| PRJEB30681 | ENA

Transcriptomic analysis of E0771 tumors treated with FEC + oHSV-1 Vs PBS

Project description:E0771 tumors were implanted either subcutaneously on the left flank or orthotopically in the mammary fat pad and treated with either PBS or FEC + oHSV-1 Mice were sacrificed 5 days after the start of treatment and whole tumour digests were used for RNA extraction

2021-10-01 | GSE183864 | GEO

Placental protein-1 (Plac1) modulates immune tolerance in mammary tumor cells

Project description:Plac1 is an X-linked (Xq26) trophoblast gene expressed at high levels in the placenta, at low levels in the testis, but not in other normal somatic tissues. However, it is re-expressed in several malignancies, including breast, colon, lung, gastric, liver and endometrial cancers as well as in most human cancer cell lines. Plac1 contains HLA-A2-restricted epitopes capable of eliciting a cytotoxic T lymphocyte (CTL) response against human breast cancer cells, and colorectal cancer patients with a Plac1-specific CTL response demonstrate long-term survival. To explore the role of Plac1 in cancer, mouse mammary tumor E0771 cells expressing high levels of Plac1 were transduced with a lentivirus expressing a Plac1 shRNA (E0771/shPlac1). The RNeasy Mini Kit was used to purify total RNA from three independent cell culture samples for gene expression analysis. After isolation in parallel, 1 Î¼g of each of the total RNA from E0771/Scram or E0771/Shplac1 was pooled prior to microarray gene expression analysis. E0771/Scram was considered as control group in this experiment.

2016-02-24 | E-GEOD-78202 | biostudies-arrayexpress

Gene expression profile at single cell level of CD45+ immune cells from E0771-Vector control tumor tissue, E0771 wildtype Malt1 overexpression tumor tissue and E0771 paracaspase-deficient Malt1 overexpression tumor tissue.

Project description:To invesitigate the additional paracaspase-independent tumor-promoting effect exist for Malt1. We thus collected E0771-Vector control tumor tissue, E0771 wildtype Malt1 (Malt1-WT) overexpression tumor tissue and E0771 paracaspase-deficient Malt1 (Malt1-PD) overexpression tumor tissue, and sorted out immune cells for 10× Genomics single cell RNA-sequencing (scRNA-seq).

2024-04-18 | GSE242554 | GEO

4T1 mouse mammary tumor RNA-seq gene expression profiling: impact of time course of metronomic cyclophosphamide treatment of triple negative breast cancer tumors implanted in female BALB/c mice

Project description:RNA-seq analysis of polyA-selected RNA isolated from frozen tumor tissue excised from adult female BALB/c mice implanted with 4T1 tumors in the mammary fat pad. Mice were treated with cyclophosphamide given on a metronomic schedule (treatment every 6 days at 130 mg/kg, or PBS (vehicle control), for a total of 2, 4 or 7 treatment cycles) (lab experiment # TD227). These tumor RNA samples were part of a study where we investigated the role of type-I interferon signaling in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190531 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data